Health

Jodi Olson has reportedly left Alphabet’s early-stage investment arm, where she had been a communications and marketing partner for roughly a decade.

The oncology analytics software developer received a top-up from investors including NEC Corporation at a unicorn valuation.

Pfizer Ventures was among the investors in Triana’s series A round and has taken a board seat at the molecular glue platform developer.

The Takeda spinoff is developing a vaccine for acute gastroenteritis caused by norovirus infection, and raised about $140m in August 2021.

The latest round raised by Everli and backed by Pernod Ricard was boosted by just over $24m from United Ventures, taking the grocery delivery service's overall funding to over $143m.

Wipro and Intel backed customer experience platform developer Lilt's $55m series C while Pfizer is buying corporate-backed respiratory virus therapeutic developer ReViral for up to $525m.

China Life Private Equity Investment and PICC Capital returned to co-lead the pharmaceutical discovery technology provider’s latest rounds, four months after it emerged from stealth.

The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.

Mitsui took part in oncology therapy developer Ensem Therapeutics' $67m series A round while Bioventus is paying up to $450m to buy the rest of portfolio company CartiHeal.

The drug retailer’s AB Health Ventures unit will focus on early to mid-stage healthcare technology providers working on areas including pharmaceutical distribution, commercialisation and pet care.

The gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.